Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

Launched by UNIVERSITY OF OKLAHOMA · Apr 28, 2025

Keywords

ClinConnect Summary

The NAT-Geno clinical trial is studying prostate cancer specifically in Native American patients. The goal is to look at tumor samples from these patients to better understand how the genes in these tumors can affect treatment options, how the cancer may grow, and what the likely outcomes might be. This research aims to help develop more personalized approaches to treating prostate cancer in Native American communities.

To be eligible for the study, participants need to be at least 18 years old, must self-identify as Native American, and have a confirmed diagnosis of prostate cancer. They also need to have their most recent tumor samples available for analysis. If someone is interested in participating, they will need to provide written consent before any study procedures. It’s important to note that this trial is not yet recruiting participants, but it represents a significant effort to enhance our understanding of prostate cancer in Native American populations.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
• • At least 18 years-of-age at the time of signature of the informed consent form (ICF).
• • Patients who self-identify as Native American.
• • Patients with a pathologically proven diagnosis of PC (any stage).
• • Availability of most recent archived tumor samples.
• Exclusion Criteria:
• • Patients not of Native American descent or identity.
• • Patient does not have archival tissue available.